FRANKFURT (Reuters) - The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose ...

Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...

Kroger’s retail rollout shifts Zepbound KwikPen distribution from direct-to-consumer to community pharmacy channels, potentially reducing friction in initiation and refills for GLP-1 obesity therapy.

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

Lilly’s momentum isn’t just about its successful clinical results, though. It’s also about the company’s constant iteration ...

The 4-dose KwikPen device supports weight reduction in patients with obesity or overweight with weight-related conditions.

EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the ...

A one-month, four-dose pen could reduce injector component consumption and assembly cycles, addressing a key constraint that has limited GLP-1 category supply reliability. Consolidation of doses may ...

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.